The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Patients with and without obesity experienced significant pain reductions and improved functioning following telerehabilitation for chronic musculoskeletal pain.

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

A novel biomarker signature combining PAF and CME predicts chronic pain risk, linking brain activity to individual pain ...

For patients with type 1 diabetes with moderate-to-severe gastrointestinal symptoms, fecal microbiota transplantation (FMT) is safe and improves clinical outcomes.

A large proportion of babies born very early need intensive care, which can be painful. But the healthcare system fails to provide pain relief to the full extent. This is shown by the largest survey ...

A large proportion of babies born very early need intensive care, which can be painful. But the health care system fails to ...